Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 9/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.34 |
| ▸ | FASN | P49327 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688864 | 1.00 | ADAM17 (0.35) | ADAM17ALDH1A1TP53HPGDADAMTS5 | |
| SCHEMBL20135345 | 1.00 | ADAM17 (0.35) | ADAM17ALDH1A1TP53HPGDADAMTS5 | |
| SCHEMBL20134744 | 0.91 | ADAMTS5 (0.37) | ADAM17ALDH1A1TP53ADAMTS5CRBN | |
| SCHEMBL20134745 | 0.91 | ADAMTS5 (0.37) | ADAM17ALDH1A1TP53ADAMTS5CRBN | |
| SCHEMBL20135527 | 0.91 | CRBN (0.37) | ADAM17ALDH1A1ADAMTS5CRBN | |
| SCHEMBL20135526 | 0.91 | CRBN (0.37) | ADAM17ALDH1A1ADAMTS5CRBN | |
| SCHEMBL20135331 | 0.88 | ADAMTS5 (0.41) | ADAM17ADAMTS5CRBN | |
| SCHEMBL20135335 | 0.88 | ADAMTS5 (0.41) | ADAM17ADAMTS5CRBN | |
| SCHEMBL29688946 | 0.88 | ADAMTS5 (0.41) | ADAM17ADAMTS5CRBN | |
| SCHEMBL20135720 | 0.88 | ADAMTS5 (0.38) | ADAM17ADAMTS5CRBNHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | ADAM17 36/4885ALDH1A1 584/4885TP53 4082/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | ADAM17 39/4885ALDH1A1 610/4885TP53 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.